"You have a weight problem, and you've tried everything, and then somebody says, 'Take this injection and you're going to be skinny,'" she said
They can help rule out other causes and make sure everything is on track
Health Canada approved Ozempic in 2018 and Wegovy in 2021, but the latter is not yet available here due to overwhelming demand in the United States and other countries
Semaglutide example (maintenance dose): Brand-name Wegovy: ~$1,350/month = ~$16,200/year Compounded (503B): ~$300/month average = ~$3,600/year Annual savings: approximately $12,600 Percentage savings: approximately 78% Tirzepatide example (maintenance dose): Brand-name Zepbound: ~$1,060/month = ~$12,720/year Compounded (503B): ~$375/month average = ~$4,500/year Annual savings: approximately $8,220 Percentage savings: approximately 65% Over a multi-year treatment course - and GLP-1 treatment is typically long-term - these savings compound dramatically
Which non-medication factors does the article's risk table say can trigger headache
This was followed by the approval of Eli Lillys Foundayo - a GLP-1 pill for adults with obesity and weight-related medical complications
